Three Doses of COVID-19 Vaccines: A Retrospective Study Evaluating the Safety and the Immune Response in Patients with Multiple Sclerosis.
AEFI
COVID-19
mRNA-based vaccine
multiple sclerosis
observational study
safety
three doses
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
23 Jun 2023
23 Jun 2023
Historique:
received:
30
05
2023
revised:
19
06
2023
accepted:
21
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Since the beginning of the mass immunization of patients with multiple sclerosis (MS), many data on the efficacy and safety of COVID-19 vaccines have been produced. Considering that MS is an autoimmune disease and that some disease-modifying therapies (DMTs) could decrease the antibody response against COVID-19 vaccines, we carried out this retrospective study with the aim to evaluate the safety of these vaccines in terms of AEFI occurrence and the antibody response after MS patients had received the third dose. Two hundred and ten patients (64.8% female; mean age: 46 years) received the third dose of the mRNA-based COVID-19 vaccine and were included in the study. Third doses were administered from October 2021 to January 2022. The majority of patients (
Identifiants
pubmed: 37445269
pii: jcm12134236
doi: 10.3390/jcm12134236
pmc: PMC10342738
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Front Pharmacol. 2021 Apr 20;12:667254
pubmed: 33959029
Hum Vaccin Immunother. 2022 Nov 30;18(6):2109365
pubmed: 35947052
J Clin Med. 2022 Nov 21;11(22):
pubmed: 36431332
Ther Adv Neurol Disord. 2013 Jul;6(4):237-48
pubmed: 23858327
Mult Scler Relat Disord. 2022 Dec;68:104119
pubmed: 36037755
J Neurol. 2022 May;269(5):2286-2292
pubmed: 35235002
Front Pharmacol. 2017 May 26;8:305
pubmed: 28603499
Expert Opin Drug Saf. 2016 Dec;15(sup2):9-15
pubmed: 27875917
Vaccines (Basel). 2023 Feb 09;11(2):
pubmed: 36851276
JAMA Neurol. 2022 Mar 1;79(3):307-309
pubmed: 35072702
Front Immunol. 2021 Dec 09;12:781843
pubmed: 34956211
Front Cell Neurosci. 2020 Oct 27;14:599717
pubmed: 33192332
Vaccine. 2017 May 2;35(19):2600-2604
pubmed: 28365252
Br J Pharmacol. 2022 May;179(10):2128-2148
pubmed: 33960398
J Headache Pain. 2022 Mar 31;23(1):41
pubmed: 35361131
Mult Scler Relat Disord. 2022 Jan;57:103458
pubmed: 34896876
Front Neurol. 2021 Aug 10;12:721502
pubmed: 34447349
EBioMedicine. 2022 Jul;81:104102
pubmed: 35759920
Mult Scler. 2023 Jun;29(7):856-865
pubmed: 37165941
J Neurol. 2023 May;270(5):2380-2391
pubmed: 36933032
Pharmacol Res. 2020 Jul;157:104849
pubmed: 32360482
Expert Opin Drug Saf. 2022 Jul;21(7):979-984
pubmed: 35189777
JAMA Neurol. 2022 Apr 01;79(4):399-404
pubmed: 35212717
Brain Sci. 2021 Jul 05;11(7):
pubmed: 34356125
J Neurol Sci. 2022 Mar 15;434:120155
pubmed: 35091386